-
Stiefel launches Sorilux foam
LONDON — Stiefel, a GlaxoSmithKline company, announced the availability of Sorilux foam by prescription.
The product is a topical treatment of plaque psoriasis in patients ages 18 years or older. Sorilux foam utilizes VersaFoam technology. VersaFoam-AEF (aqueous-based emulsion formulation) is free of ethanol, preservatives, parabens and fragrance, Stiefel said. The company also noted the foam is the only vitamin D3 analog treatment in a topical foam formulation.
-
Mental health, medicines top of mind for industry
In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.
The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.